JP2023534636A5 - - Google Patents

Info

Publication number
JP2023534636A5
JP2023534636A5 JP2023501003A JP2023501003A JP2023534636A5 JP 2023534636 A5 JP2023534636 A5 JP 2023534636A5 JP 2023501003 A JP2023501003 A JP 2023501003A JP 2023501003 A JP2023501003 A JP 2023501003A JP 2023534636 A5 JP2023534636 A5 JP 2023534636A5
Authority
JP
Japan
Prior art keywords
amino acid
wild
acid substitution
position corresponding
type cat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023501003A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023534636A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/038714 external-priority patent/WO2022010652A1/en
Publication of JP2023534636A publication Critical patent/JP2023534636A/ja
Publication of JP2023534636A5 publication Critical patent/JP2023534636A5/ja
Pending legal-status Critical Current

Links

JP2023501003A 2020-07-10 2021-06-23 治療薬のネコにおける半減期を増加させるための組成物及びその使用方法 Pending JP2023534636A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063050535P 2020-07-10 2020-07-10
US63/050,535 2020-07-10
US202163143720P 2021-01-29 2021-01-29
US63/143,720 2021-01-29
PCT/US2021/038714 WO2022010652A1 (en) 2020-07-10 2021-06-23 Compositions for increasing half-life of a therapeutic agent in felines and methods of use

Publications (2)

Publication Number Publication Date
JP2023534636A JP2023534636A (ja) 2023-08-10
JP2023534636A5 true JP2023534636A5 (https=) 2024-07-01

Family

ID=77043030

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023501003A Pending JP2023534636A (ja) 2020-07-10 2021-06-23 治療薬のネコにおける半減期を増加させるための組成物及びその使用方法

Country Status (11)

Country Link
US (4) US11498953B2 (https=)
EP (1) EP4178977A1 (https=)
JP (1) JP2023534636A (https=)
KR (1) KR20230038522A (https=)
CN (2) CN116096741B (https=)
AU (1) AU2021306179A1 (https=)
BR (1) BR112022027028A2 (https=)
CA (1) CA3188448A1 (https=)
MX (1) MX2023000500A (https=)
TW (1) TW202216749A (https=)
WO (1) WO2022010652A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
US12297272B2 (en) 2017-08-15 2025-05-13 Eianco US inc. IgG Fc variants for veterinary use
CN113544153B (zh) 2019-01-03 2024-12-10 因外泰克斯公司 用于增加治疗剂在犬中的半衰期的组合物及使用方法
CN120590527A (zh) 2020-05-11 2025-09-05 因外泰克斯公司 用于增加治疗剂在犬中的半衰期的组合物和使用方法
JP7796415B2 (ja) * 2020-06-10 2026-01-09 株式会社バイカ・セラピュティクス エリスロポエチンポリペプチドを含む融合タンパク質
KR20230038522A (ko) 2020-07-10 2023-03-20 인베티엑스 인코포레이티드 고양이에서 치료제의 반감기를 증가시키기 위한 조성물 및 사용 방법
EP4255933A4 (en) * 2020-12-07 2025-07-23 Invetx Inc COMPOSITIONS FOR INCREASING THE HALF-LIFE OF A THERAPEUTIC AGENT IN LIVESTOCK ANIMALS AND METHODS OF USE
KR20230121056A (ko) * 2020-12-18 2023-08-17 조에티스 서비시즈 엘엘씨 고양이 항체 불변 영역의 돌연변이
WO2024145280A2 (en) 2022-12-27 2024-07-04 Invetx, Inc. Polypeptides with altered binding to neonatal fc receptor (fcrn) and methods of use
AU2024210302A1 (en) 2023-01-20 2025-09-04 Invetx, Inc. Bispecific binding agents for use in companion animals
EP4662227A1 (en) * 2023-02-08 2025-12-17 Levicept Limited Fusion protein

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US5683888A (en) 1989-07-22 1997-11-04 University Of Wales College Of Medicine Modified bioluminescent proteins and their use
US5292658A (en) 1989-12-29 1994-03-08 University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center Cloning and expressions of Renilla luciferase
ES2142801T3 (es) 1991-03-11 2000-05-01 Univ Georgia Res Found Clonacion y expresion de luciferasa de renilla.
EP0759170B1 (en) 1993-09-10 2008-07-09 The Trustees Of Columbia University In The City Of New York Uses of green fluorescent protein
WO1995021191A1 (en) 1994-02-04 1995-08-10 William Ward Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
US5777079A (en) 1994-11-10 1998-07-07 The Regents Of The University Of California Modified green fluorescent proteins
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US5804387A (en) 1996-02-01 1998-09-08 The Board Of Trustees Of The Leland Stanford Junior University FACS-optimized mutants of the green fluorescent protein (GFP)
US5876995A (en) 1996-02-06 1999-03-02 Bryan; Bruce Bioluminescent novelty items
US5925558A (en) 1996-07-16 1999-07-20 The Regents Of The University Of California Assays for protein kinases using fluorescent protein substrates
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
IL129767A0 (en) 1996-12-12 2000-02-29 Prolume Ltd Apparatus and method for detecting and identifying infectious agents
JP2002507410A (ja) 1998-03-27 2002-03-12 プロルーム・リミテッド ルシフェラーゼ、蛍光タンパク質、ルシフェラーゼおよび蛍光タンパク質をコードする核酸および、診断、高処理スクリーニングおよび新規アイテムにおけるその使用
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
AU2005274905B2 (en) * 2004-08-04 2010-12-23 Mentrik Biotech, Llc Variant Fc regions
AU2005285347A1 (en) * 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
US8546543B2 (en) * 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
CN101098890B (zh) * 2004-11-12 2012-07-18 赞科股份有限公司 对FcRn的结合被改变的Fc变体
US8802820B2 (en) * 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
EP2411050A4 (en) 2009-03-25 2013-07-17 Vet Therapeutics Inc ANTIBODY REGIONS WITH A CONSTANT DOMAIN AND THEIR USE
WO2010117448A2 (en) 2009-04-05 2010-10-14 Provenance Biopharmaceuticals Corp. Chimeric immunocytokines and methods of use thereof
GB2504887B (en) 2011-05-06 2016-02-03 Nvip Pty Ltd Anti-Nerve growth factor antibodies and methods of preparing and using the same
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
US20130129727A1 (en) 2011-11-17 2013-05-23 Nanjingjinsirui Science & Technology Biology Corporation Methods and systems for increasing protein stability
US20140294812A1 (en) * 2013-03-15 2014-10-02 Xencor, Inc. Fc variants that improve fcrn binding and/or increase antibody half-life
EP3194429A4 (en) 2014-09-18 2018-06-13 Askgene Pharma, Inc. Novel feline erythropoietin receptor agonists
EP3448427A1 (en) 2016-04-29 2019-03-06 CureVac AG Rna encoding an antibody
EP3481413A4 (en) 2016-07-08 2020-01-08 Askgene Pharma, Inc. FUSION PROTEIN WITH LEPTIN AND METHOD FOR THE PRODUCTION AND USE THEREOF
US20200181258A1 (en) 2016-10-17 2020-06-11 Vetoquinol Sa Modified antibody constant region
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
US12297272B2 (en) 2017-08-15 2025-05-13 Eianco US inc. IgG Fc variants for veterinary use
BR112020017701A2 (pt) 2018-03-12 2020-12-29 Zoetis Services Llc Anticorpos anti-ngf e métodos dos mesmos
CA3093539A1 (en) 2018-03-16 2019-09-19 Zoetis Services Llc Interleukin-31 monoclonal antibodies for veterinary use
JP2022500037A (ja) 2018-09-14 2022-01-04 キンドレッド バイオサイエンシズ インコーポレイテッド 獣医学的使用のための抗ｉｌ４受容体抗体
US20210388053A1 (en) 2018-10-18 2021-12-16 Kindred Biosciences, Inc. Fc Variants with Altered Binding to Neonatal Fc Receptor (FCRN) for Veterinary Use
JP7536294B2 (ja) 2018-12-05 2024-08-20 株式会社バイカ・セラピュティクス 抗体のＦｃ領域改変体
CN120904316A (zh) 2018-12-27 2025-11-07 伊兰科美国公司 兽用IgG Fc变体
CN113544153B (zh) 2019-01-03 2024-12-10 因外泰克斯公司 用于增加治疗剂在犬中的半衰期的组合物及使用方法
WO2021165417A1 (en) 2020-02-19 2021-08-26 Adivo Gmbh Modified fc regions
CN115996949A (zh) 2020-04-17 2023-04-21 硕腾服务有限责任公司 犬抗体变异体
MX2022012793A (es) 2020-04-17 2022-11-07 Zoetis Services Llc Variantes de anticuerpos felinos.
CN120590527A (zh) 2020-05-11 2025-09-05 因外泰克斯公司 用于增加治疗剂在犬中的半衰期的组合物和使用方法
US20220119513A1 (en) 2020-06-08 2022-04-21 Zoetis Services Llc Anti-tgfb antibodies and therapeutic uses thereof
KR20230038522A (ko) 2020-07-10 2023-03-20 인베티엑스 인코포레이티드 고양이에서 치료제의 반감기를 증가시키기 위한 조성물 및 사용 방법
MX2023004020A (es) 2020-10-07 2023-07-07 Zoetis Services Llc Anticuerpos anti-ngf y métodos para su uso.
TWI904261B (zh) 2020-10-19 2025-11-11 美商碩騰服務公司 犬及貓抑瘤素Ｍ受體β之抗體及其用途
KR20230121056A (ko) 2020-12-18 2023-08-17 조에티스 서비시즈 엘엘씨 고양이 항체 불변 영역의 돌연변이
CA3238769A1 (en) 2021-11-23 2023-06-01 William Brondyk Anti-ngf antibodies and uses thereof

Similar Documents

Publication Publication Date Title
JP2023534636A5 (https=)
AU2022218544B2 (en) Hetero-dimeric multi-specific antibody format
JP2023526225A5 (https=)
WO2020142625A4 (en) Compositions for increasing half-life of a therapeutic agent in canines and methods of use
CN110234355B (zh) 单体人IgG1 Fc和双特异性抗体
JP7264383B2 (ja) 血中半減期の向上のための抗体Ｆｃ変異体
WO2005040217B1 (en) Antibodies having a mutated amino acid residue at position 268 (ch2 region) in constant regions
JP2016506377A (ja) 抗体重鎖不変部位の異種二量体、高効率の形成を誘導するｃｈ３ドメイン変異体対、その作製方法および用途
US11401299B2 (en) Generating multispecific antibody mixtures and methods of uses thereof
KR102730638B1 (ko) pH-감응성 Fc 변이체
JP7634545B2 (ja) ｐＨ感応性ＦＣ変異体
JP2023553694A5 (https=)
Abraha et al. The preparation and characterization of monoclonal antibodies to human complement component C8 and their use in purification of C8 and C8 subunits
JP2023552456A5 (https=)
AU674523B2 (en) An interferon-alpha/beta binding protein its preparation and pharmaceutical compositions containing it
CN117264054B (zh) 靶向il-6的纳米抗体、组合物、方法及用途
AU2020270242B2 (en) Anti-TNF-α humanized monoclonal antibody TCX060 having low immunogenicity and low ADCC/CDC function, and use thereof
JP2024522092A5 (https=)
CN115246885B (zh) 一种双特异性抗体及其应用
JP2019172702A (ja) 目的とする含量で不純物を含むＴＮＦＲ−Ｆｃ融合タンパク質の製造方法
JP2024546916A5 (https=)
JP2023525555A5 (https=)
RU2021122918A (ru) Композиции для увеличения периода полужизни терапевтического средства у собак и способы применения
JP2024531346A5 (https=)
RU2815826C2 (ru) Получение мультиспецифических смесей антител и способы их применения